01885

Docetaxel

purum, ≥97.0% (HPLC)

• Synonyme(s) : Docetaxel anhydrous
• Formule empirique (notation de Hill): C₄₃H₅₃NO₁₄
• Numéro CAS: 114977-28-5
• Poids moléculaire : 807.88
• Numéro MDL: MFCD00800737
• Code UNSPSC : 51101929
• ID de substance PubChem : 329747367
• Nomenclature NACRES : NA.25

Propriétés

• Qualité: purum
• Niveau de qualité: 200
• Pureté: ≥97.0% (HPLC)
• Forme: powder or crystals
• Impuretés: ~6% water
• Pf: 186-192 °C (dec.)
• Application(s): metabolomics; vitamins, nutraceuticals, and natural products
• Chaîne SMILES: [H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c5ccccc5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c6ccccc6
• InChI: 1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1
• Clé InChI: ZDZOTLJHXYCWBA-VCVYQWHSSA-N
• Informations sur le gène: human ... TUBA1A(7846) , TUBA1B(10376) , TUBA1C(84790) , TUBA3C(7278) , TUBA3E(112714) , TUBA4A(7277) , TUBB(203068) , TUBB1(81027) , TUBB2A(7280) , TUBB2B(347733) , TUBB3(10381) , TUBB4A(10382) , TUBB4B(10383) , TUBB6(84617) , TUBB8(347688)

Description

Description générale

Docetaxel is a cytotoxic, semisynthetic, second-generation taxane derived from the needles of the European yew tree , with a baccatin ring , and is an anthracycline antibiotic. It is related to paclitaxel but structurally it differs from paclitaxel on the 3′ position of the side chain and 10′ position of the baccatin ring.

Application

Docetaxel has been used:

• to test its effect on lysosomal autophagic flux in gastric cancer cells
• in combination with stearidonic acid (SDA) to increase its efficacy and enhancing cell death in human prostate cancer cells
• as a microtubule-stabilizing agent in prostate and cervical cancer cells
• in combination with a γ-secretase inhibitor (GSI) in prostate cancer stem-like cells (PCSCs) to test its effect on the notch signaling pathway

Actions biochimiques/physiologiques

Docetaxel (DOC) is an anti-microtubule agent , a standard anti-cancer drug used in first-line chemotherapy treatment in many types of cancer including prostate and breast cancer. It elicits a stronger effect of inhibiting angiogenesis in both in vitro and in vivo by acting on vascular endothelial growth factor (VEGF) associated with tumor cells. Being involved in many key cellular processes such as cell cycle, angiogenesis, and gene expression; docetaxel interacts with many signaling pathways, such as the epidermal growth factor receptor (EGFR) pathway, Ras pathway, etc.

Docetaxel is a taxane anti-cancer agent related to paclitaxel. It binds to and stabilizes the β−tubulin subunit of microtubules, preventing depolymerization of the mitotic spindle thus leading to cell cycle arrest and apoptosis.

Conditionnement

Bottomless glass bottle. Contents are inside inserted fused cone.

Informations sur la sécurité

• Pictogrammes: GHS08,GHS07
• Mention d'avertissement: Danger
• Mentions de danger: H315,H319,H341,H360D,H362,H372
• Conseils de prudence: P202 - P260 - P263 - P302 + P352 - P305 + P351 + P338 - P308 + P313
• Classification des risques: Eye Irrit. 2 - Lact. - Muta. 2 - Repr. 1B - Skin Irrit. 2 - STOT RE 1
• Code de la classe de stockage: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• Classe de danger pour l'eau (WGK): WGK 3
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable
• Équipement de protection individuelle: Eyeshields, Gloves, type N95 (US)